Elekta stock falls as JPMorgan keeps negative watch

Published on 09/09/2026 at 19:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elekta stock was down 1.7 percent in Stockholm on September 9, 2026, after JPMorgan kept it on negative watch. Barclays still had a SEK 45.50 target on September 1, 2026.

Flatlay mit Aktienzertifikat, ISIN-Karte und medizinischen Utensilien auf weißem Untergrund — Flatlay-Arrangement mit Aktienzertifikat und ISIN-Karte SE0000163628 zeigt Investment-Utensilien passend zur Branche von Elekta AB, Illustration mit AI erstellt.

Elekta stock (SE0000163628) traded at SEK 49.32 on September 9, 2026, after sliding 0.96 percent on the day, while MarketScreener showed a Stockholm quote of SEK 49.72 on October 21, 2025 and a year-to-date move of -18.69 percent.

Analysts stayed cautious

JPMorgan kept Elekta under negative catalyst watch ahead of the American Society for Radiation Oncology meeting running September 26-30, 2026, according to Investing.com on September 9, 2026. The same report said Elekta was rated underweight and that a new product launch by Varian was viewed as a headwind.

On September 1, 2026, Barclays kept its sell call and set a price target of SEK 45.50, while JPMorgan kept a SEK 46.20 target on August 28, 2026, according to Investing.com. The average 12-month target on that page was SEK 59.69, with 14 analysts in the consensus set and a range from SEK 41 to SEK 100.

Revenue and margin

Investing.com said Elekta's latest quarterly figures showed revenue of SEK 3,536.00 million, net profit of SEK 264.00 million and EBITDA of SEK 504.00 million. The same page listed EBIT margin at 10.49 percent and gross margin at 42.56 percent, giving investors a current operating snapshot tied to the most recent quarter.

The company profile page on MarketScreener listed Elekta's 2026 net sales at SEK 17.72 billion, net income at SEK 1.29 billion and net debt at SEK 4.25 billion. On the same page, the 2027 estimate rose to SEK 18.67 billion in sales and SEK 1.53 billion in net income, which implies a higher earnings base in the forward model.

Stock stays below target

For investors, the gap between SEK 49.32 and Barclays' SEK 45.50 target is narrow, but it still leaves the shares below the average consensus of SEK 59.69. Elekta closed the session with a 52-week range of SEK 41.86 to SEK 66.70 on the Investing.com consensus page.